Journal of Clinical Oncology
Articles in this Issue
Real-world outcomes and toxicity with belzutifan in the treatment of Von Hippel–Lindau disease: A single centre Canadian experience.
e22620 Background: Von Hippel–Lindau (VHL) disease is an autosomal dominant disorder caused by mutations in the VHL gene, predispo...
Investigation of clonal hematopoiesis frequency following PARP inhibitor treatment and its association with prior platinum therapy exposure.
e15017 Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) have become a critical part of treatment for multiple solid tumors, especially among pa...
Leveraging real-world data sources for clinical oncology research: A review of studies published in ASCO publications.
11178 Background: Real-world data (RWD) are essential for assessing healthcare delivery and outcomes for cancer survivors, require complex statistical tec...
Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.
5001 Background: The STAMPEDE trials showed that adding abiraterone acetate + prednisolone (AAP) ± enzalutamide (ENZ) to standard of care androgen depriva...
The effect of transportation services on completion of radiation therapy for gynecologic malignancies.
e13502 Background: Optimization of outcomes for gynecologic oncology patients undergoing radiation therapy (RT) depends on timely completion of treatment....
Spotlight on pre-chemotherapy alpha-fetoprotein and survival in ovarian yolk sac tumors.
e17589 Background: Ovarian yolk sac tumor (OYST) is a rare malignancy, accounting for 20% of malignant ovarian germ cell tumors and 1% of all ovarian canc...
Association of body mass index change and insulin resistance with survival during induction therapy in newly diagnosed multiple myeloma.
e24076 Background: Elevated BMI is a known risk factor in newly diagnosed multiple myeloma (NDMM), with extremes (underweight and obese) linked to worse s...
Real-world comparison of anti-BCMA vs anti-GPRC5D BiTE therapy in relapsed/refractory multiple myeloma without prior CAR-T cell exposure.
7542 Background: In recent years, three bispecific T-cell engager (BiTE) agents have been approved for Refractory/Relapsed Multiple Myeloma (rrMM). These...
A longitudinal analysis of social networks and patient-reported outcomes among young adult cancer survivors.
12111 Background: Nearly 80,000 young adults (YAs; aged 18-39) are diagnosed with cancer each year in the United States with > 80% expected to survive...
Reduced length of stay as an alternative to full outpatient CAR-T services.
e13575 Background: Cellular therapies continue to expand in diversity, complexity, and financial impact leading clinicians and administrators to seek inno...
The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma.
TPS9598 Background: Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer driven by UV mutations or the Merkel cell polyomavirus (MCPyV).It is...
The efficacy and safety of donafenib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective study.
e16272 Background: The recurrence rate of hepatocellular carcinoma (HCC) after hepatectomy is still high. Despite the advance in treatment , there is no g...
Exploring the role of professional cancer societies in spreading awareness about oncology to undergraduate medical students: Experiences from Tamil Nadu, India.
e21013 Background: Medical students in India are not formally exposed to evidence based, multi-disciplinary oncology care in their undergraduate curriculu...
Comparative efficacy of ibrutinib versus other covalent Bruton tyrosine kinase inhibitors (cBTKis) in first-line (1L) chronic lymphocytic leukemia (CLL): A matched-adjusted indirect comparison (MAIC).
e19023 Background: Ibrutinib (ibr), acalabrutinib (acala), and zanubrutinib (zanu) are cBTKis approved for treatment of CLL, with demonstrated efficacy as...
Targeting ALKBH5 with cisplatin-Ga nanodrug to investigate platinum sensitivity in resistant ovarian cancer through m6A-dependent mechanisms.
e17595 Background: Platinum-based combination chemotherapy remains a cornerstone in the treatment of ovarian cancer. However, the development of platinum...
Real-world data on the efficacy and safety of iruplinalkib (WX-0593) in ALK-positive advanced lung adenocarcinoma patients previously treated with lorlatinib.
8638 Background: Iruplinalkib (WX-0593) is a novel anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI). Here we report the results from a ret...
Real-world outcomes of CAR-T in the outpatient setting.
e19015 Background: Chimeric antigen receptor T (CAR-T) cell therapy has changed the treatment paradigm of relapsed/refractory (R/R) B cell malignancies an...
Study on prevention of recurrence in patients with NMIBC for whom BCG vaccine treatment failed by hematoporphyrin intravesical perfusion photodynamic therapy (PDT) combined with intravesical perfusion therapy.
e16592 Background: To explore the efficacy and safety of hematoporphyrin intravesical perfusion PDT eracombined with intravesical perfusion therapy in pre...
Optimizing treatment strategies for synchronous malignancies: Integrating overlapping regimens for improved outcomes.
e23086 Background: The management of synchronous dual malignancies is a therapeutic challenge in oncology clinics due to lack of clinical research. The di...
Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab.
1052 Background: The CLEOPATRA and PERUSE trials established the combination of a taxane with the antiHER2 monoclonal antibodies trastuzumab and pertuzuma...
Safety and efficacy of NK-1 receptor antagonist–based therapy for prevention and treatment of chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy: A systematic review and meta-analysis.
e24123 Background: Chemotherapy-induced nausea and vomiting (CINV) significantly impact the quality of life for patients receiving highly emetogenic chemo...
Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow up patients across cancer types.
e14540 Background: India presents diverse genetic pool and varying cancer incidence patterns. Common cancers in the Indian...
Pediatric cancer registry in Turkey 2002-2024 (TPOG and TPHD): The data from the last 23 years.
e22012 Background: Each year more than 400.000 new pediatric cancer cases are expected in children and adolescents aged 0-14 globally. The improvement of...
Sex differences in toxicities among patients receiving regorafenib or trifluridine/tipiracil for refractory metastatic colorectal cancer: A subgroup analysis from the multicenter retrospective ReTrITA study.
e15589 Background: A mounting body of evidence indicates the existence of sex disparities in the prevalence, severity, and prognosis of various cancers. I...
Effect of H3K18 lactylation in cancer-associated fibroblasts on malignant pleural effusion progression via recruiting of TNFR2 <sup>+</sup> Tregs.
e20028 Background: TNFR2 + Tregs, which are recognized as the maximally suppressive subset of Tregs, play a pivotal role in mainta...